Join
Live feed
·
PRReleasevia Quantisnow
MAIA Biotechnology Inc. logo

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

ByQuantisnow·Wall Street's wire, on your screen.
MAIA· MAIA Biotechnology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MAIA (MAIA Biotechnology Inc.) and more on Quantisnow.